Role of imaging biomarkers in mutation-driven non-small cell lung cancer

Table 2 Commonly used platforms for detection of mutations in non-small cell lung cancer

Testing technique	High sensitivityin detecting	Lower sensitivityin detecting
Direct gene sequencing		BRAF
Requires high tumor cellularity		EGFR
Largely replaced by newer techniques		HER2
		KRAS
Allele specific sequencing	BRAF
Detects predefined abnormalities	EGFR
Allows for multiplex testing	HER2
	KRAS
	METex14 skipping
Next Generation sequencing	BRAF	ALK
Can detect novel mutations	EGFR	RET
Allows for multiplex testing	HER2	ROS1
Can be costly and time consuming	KRAS	NTRK
	METex14 skipping	MET amplification
Fluorescent in situ hybridization	ALK
	RET
	ROS1
	NTRK
	MET amplification
Immunohistochemistry Also used to detect PD-L1 protein expression	ALKROS1	NTRK fusion